These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 31789400)
1. Protein‑ and growth‑modulatory effects of carcinoma‑associated fibroblasts on breast cancer cells: Role of interleukin‑6. Dittmer A; Lange T; Leyh B; Dittmer J Int J Oncol; 2020 Jan; 56(1):258-272. PubMed ID: 31789400 [TBL] [Abstract][Full Text] [Related]
2. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361 [TBL] [Abstract][Full Text] [Related]
3. Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis. Leyh B; Dittmer A; Lange T; Martens JW; Dittmer J Oncotarget; 2015 Nov; 6(36):39307-28. PubMed ID: 26515727 [TBL] [Abstract][Full Text] [Related]
4. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer. Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals. Huang J; Woods P; Normolle D; Goff JP; Benos PV; Stehle CJ; Steinman RA Breast Cancer Res Treat; 2017 Jan; 161(2):229-243. PubMed ID: 27853906 [TBL] [Abstract][Full Text] [Related]
6. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway. Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447 [TBL] [Abstract][Full Text] [Related]
7. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Beeram M; Tan QT; Tekmal RR; Russell D; Middleton A; DeGraffenried LA Ann Oncol; 2007 Aug; 18(8):1323-8. PubMed ID: 17693645 [TBL] [Abstract][Full Text] [Related]
8. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612 [TBL] [Abstract][Full Text] [Related]
9. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290 [TBL] [Abstract][Full Text] [Related]
10. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Hiscox S; Jordan NJ; Jiang W; Harper M; McClelland R; Smith C; Nicholson RI Endocr Relat Cancer; 2006 Dec; 13(4):1085-99. PubMed ID: 17158755 [TBL] [Abstract][Full Text] [Related]
11. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946 [TBL] [Abstract][Full Text] [Related]
12. Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin. Delort L; Bougaret L; Cholet J; Vermerie M; Billard H; Decombat C; Bourgne C; Berger M; Dumontet C; Caldefie-Chezet F Nutrients; 2019 Nov; 11(12):. PubMed ID: 31756890 [TBL] [Abstract][Full Text] [Related]
13. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289 [TBL] [Abstract][Full Text] [Related]
14. Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells. Nukatsuka M; Saito H; Noguchi S; Takechi T In Vivo; 2019; 33(5):1439-1445. PubMed ID: 31471390 [TBL] [Abstract][Full Text] [Related]
15. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472 [TBL] [Abstract][Full Text] [Related]
16. The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines. Kirkegaard T; Yde CW; Kveiborg M; Lykkesfeldt AE Int J Oncol; 2014 Jul; 45(1):393-400. PubMed ID: 24819550 [TBL] [Abstract][Full Text] [Related]
18. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. Liu H; Cheng D; Weichel AK; Osipo C; Wing LK; Chen B; Louis TE; Jordan VC Int J Oncol; 2006 Nov; 29(5):1237-46. PubMed ID: 17016657 [TBL] [Abstract][Full Text] [Related]
19. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263 [TBL] [Abstract][Full Text] [Related]
20. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells. Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]